06.02.2018 16:25:00

Valeant Will Release Fourth-Quarter And Full-Year 2017 Financial Results On February 28

LAVAL, Quebec, Feb. 6, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") will release its fourth-quarter and full-year 2017 financial results on Wednesday, Feb. 28, 2018. Valeant will host a conference call and live web cast at 8:00 a.m. EST to discuss the results and provide a business update. All materials will be made available on the investor relations section of the Valeant web site prior to the start of the call.

 

Conference Call Details

Date:

Wednesday, Feb. 28, 2018

Time:

8:00 a.m. EST

Webcast:

http://ir.valeant.com/events-and-presentations

Participant Event Dial-in: 

(844) 428-3520 (North America)


(409) 767-8386 (International)

Participant Passcode:

5287247

Replay Dial-in:

(855) 859-2056 (North America)


(404) 537-3406 (International)

Replay Passcode:

5287247 (replay available until Apr. 28, 2018)

 

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

 

Investor Contact:

Media Contact:  

Arthur Shannon

Lainie Keller

arthur.shannon@valeant.com

lainie.keller@valeant.com

(514) 856-3855              

(908) 927-0617

(877) 281-6642 (toll free)


 

Valeant Pharmaceuticals International, Inc. (PRNewsFoto/Valeant Pharmaceuticals International, Inc.) (PRNewsFoto/)

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/valeant-will-release-fourth-quarter-and-full-year-2017-financial-results-on-february-28-300594219.html

SOURCE Valeant Pharmaceuticals International, Inc.

Nachrichten zu Valeant Pharmaceuticals International Inc.mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Valeant Pharmaceuticals International Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!